Stocktoria
Clearside Biomedical, Inc. CLSDQ
Clearside Biomedical, Inc. (CLSDQ) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2024 revenue was $1.7M at a -2064.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.34 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1965 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CLSDQ | Clearside Biomedical, Inc. | 2/9 | — | — | — |
| RANI | Rani Therapeutics Holdings, Inc. | 4/9 | -4.67 | — | — |
| NRXP | NRX Pharmaceuticals, Inc. | 4/9 | — | — | — |
| BIOE | Bio Essence Corp | 9/9 | — | 14.1 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | 4/9 | — | — | — |
| LPCN | Lipocine Inc. | — | — | — | -82.3% |
| ORMP | ORAMED PHARMACEUTICALS INC. | 2/9 | 7.8 | 3 | — |
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
FAQ
Is CLSDQ financially healthy?
Clearside Biomedical, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does CLSDQ pay a dividend?
No, Clearside Biomedical, Inc. does not currently pay a dividend.
How profitable is CLSDQ?
In FY2024, Clearside Biomedical, Inc. had a net margin of -2064.4%.
Is CLSDQ a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Clearside Biomedical, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2024-12-31. Facts plus Stocktoria's own computed scores — not investment advice.